Efficiently Creating Value with Innovative Science


NASDAQ: OXGN

$ 0.54 0.00 (0.00%)
Day High: N/A
Day Low:  N/A
Volume:    N/A
3:59 PM ET
Feb 9, 2016

Delayed ~20 min., by eSignal.

Press Releases

 
Press Releases
Date Title and Summary View
Feb 3, 2016 SOUTH SAN FRANCISCO, Calif., Feb. 03, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced it will present a company overview on February 8, 2016 at 11:30 a.m. Eastern time at the 2016 BIO CEO & Investor Forum. ...
Jan 6, 2016 SOUTH SAN FRANCISCO, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to CA4P for the treatment of neuroendocrine tumors. T...
Dec 17, 2015 SOUTH SAN FRANCISCO, Calif., Dec. 17, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced that the European Commission has granted orphan drug designation to OXi4503 for the treatment of acute myeloid leukemia (AML). The designa...
Nov 10, 2015 SOUTH SAN FRANCISCO, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today reported financial results for the quarter ended September 30, 2015. For the third quarter of 2015, OXiGENE reported a net loss of $3.6 millio...
Nov 5, 2015 SOUTH SAN FRANCISCO, Calif., Nov. 5, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents (VDAs) for the treatment of cancer, today announced initial data from a Phase 1b/2 study of the company's lead investigational drug, CA4P, in combination with the anti-angiogenic agent Votrient...
Oct 21, 2015 First patient dosed in OXiGENE-sponsored expansion of investigator trial Phase 1b/2 dose-escalation study of OXi4503 as a single agent and in combination with cytarabine SOUTH SAN FRANCISCO, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing vascular disrupting agents ...
Oct 19, 2015 -- Biomarker results in first nine subjects add to CA4P evidence of activity -- -- Full results are expected in the second half of 2016 -- SOUTH SAN FRANCISCO, Calif., Oct. 19, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel cancer therapeutics, today announced the presentation of inte...
Oct 16, 2015 SOUTH SAN FRANCISCO, Calif., Oct. 16, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage biopharmaceutical company developing novel cancer therapeutics, today announced that it will present a company overview at the 14th Annual BIO Investor Forum. The BIO Investor Forum will be held October 20-21 at the Parc 55 Hotel in San Fran...
Sep 29, 2015 Company plans to conduct two new phase 2/3 randomized studies in ovarian cancer and glioblastoma multiforme Both studies combine CA4P with an approved anti-VEGF treatment with a complementary mechanism of action Studies expected to provide most rapid path to additional efficacy data for CA4P Company to host conferenc...
Aug 4, 2015 SOUTH SAN FRANCISCO, Calif., Aug. 4, 2015 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a biopharmaceutical company developing novel therapies for treatment of cancer, today reported financial results for the quarter ended June 30, 2015. For the second quarter of 2015, OXiGENE reported a net loss of $3.3 million compared to a net loss of...
Page:
1
... NextLast
= add release to Briefcase